262 related articles for article (PubMed ID: 9041356)
21. Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis.
Koga M; Yuki N; Hirata K
J Neuroimmunol; 1999 May; 96(2):245-50. PubMed ID: 10337924
[TBL] [Abstract][Full Text] [Related]
22. Guillain-Barré syndrome and Fisher's syndrome following Campylobacter jejuni infection.
Yuki N; Miyatake T
Ann N Y Acad Sci; 1998 Jun; 845():330-40. PubMed ID: 9668366
[TBL] [Abstract][Full Text] [Related]
23. [Pathogenesis of Guillain-Barré syndrome and Fisher's syndrome: molecular mimicry between antecedent infectious agents and components of nerve tissues].
Yuki N
Rinsho Shinkeigaku; 1995 Dec; 35(12):1373-5. PubMed ID: 8752400
[TBL] [Abstract][Full Text] [Related]
24. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections.
Hao Q; Saida T; Kuroki S; Nishimura M; Nukina M; Obayashi H; Saida K
J Neuroimmunol; 1998 Jan; 81(1-2):116-26. PubMed ID: 9521613
[TBL] [Abstract][Full Text] [Related]
25. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry.
Koga M; Gilbert M; Li J; Koike S; Takahashi M; Furukawa K; Hirata K; Yuki N
Neurology; 2005 May; 64(9):1605-11. PubMed ID: 15883324
[TBL] [Abstract][Full Text] [Related]
26. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis.
Vriesendorp FJ; Mishu B; Blaser MJ; Koski CL
Ann Neurol; 1993 Aug; 34(2):130-5. PubMed ID: 8338337
[TBL] [Abstract][Full Text] [Related]
27. Campylobacter coli enteritis and Guillain-Barré syndrome: no evidence of molecular mimicry and serological relationship.
Funakoshi K; Koga M; Takahashi M; Hirata K; Yuki N
J Neurol Sci; 2006 Jul; 246(1-2):163-8. PubMed ID: 16600306
[TBL] [Abstract][Full Text] [Related]
28. [Guillain-Barré syndrome].
Yuki N
Nihon Rinsho; 1994 Nov; 52(11):2952-8. PubMed ID: 7996693
[TBL] [Abstract][Full Text] [Related]
29. Siglec-7 specifically recognizes Campylobacter jejuni strains associated with oculomotor weakness in Guillain-Barré syndrome and Miller Fisher syndrome.
Heikema AP; Jacobs BC; Horst-Kreft D; Huizinga R; Kuijf ML; Endtz HP; Samsom JN; van Wamel WJ
Clin Microbiol Infect; 2013 Feb; 19(2):E106-12. PubMed ID: 23173866
[TBL] [Abstract][Full Text] [Related]
30. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome.
Koga M; Takahashi M; Masuda M; Hirata K; Yuki N
Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859
[TBL] [Abstract][Full Text] [Related]
31. Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barré syndrome.
Neisser A; Schwerer B; Bernheimer H; Moran AP
J Neuroimmunol; 2000 Jan; 102(1):85-8. PubMed ID: 10626671
[TBL] [Abstract][Full Text] [Related]
32. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.
Schwerer B; Neisser A; Bernheimer H
Infect Immun; 1999 May; 67(5):2414-20. PubMed ID: 10225903
[TBL] [Abstract][Full Text] [Related]
33. GM1 antibody in Guillain-Barre syndrome after Campylobacter jejuni infection.
Tang J; Yuan J; Hao H
Chin Med J (Engl); 1995 Apr; 108(4):262-4. PubMed ID: 7789212
[TBL] [Abstract][Full Text] [Related]
34. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.
Yuki N
Lancet Infect Dis; 2001 Aug; 1(1):29-37. PubMed ID: 11871407
[TBL] [Abstract][Full Text] [Related]
35. Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome.
Yuki N; Ichihashi Y; Taki T
J Neuroimmunol; 1995 Jul; 60(1-2):161-4. PubMed ID: 7543907
[TBL] [Abstract][Full Text] [Related]
36. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics.
St Charles JL; Bell JA; Gadsden BJ; Malik A; Cooke H; Van de Grift LK; Kim HY; Smith EJ; Mansfield LS
J Autoimmun; 2017 Feb; 77():11-38. PubMed ID: 27939129
[TBL] [Abstract][Full Text] [Related]
37. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome.
Jacobs BC; Endtz H; van der Meché FG; Hazenberg MP; Achtereekte HA; van Doorn PA
Ann Neurol; 1995 Feb; 37(2):260-4. PubMed ID: 7531419
[TBL] [Abstract][Full Text] [Related]
38. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry.
Oomes PG; Jacobs BC; Hazenberg MP; Bänffer JR; van der Meché FG
Ann Neurol; 1995 Aug; 38(2):170-5. PubMed ID: 7654064
[TBL] [Abstract][Full Text] [Related]
39. Experimental axonopathy induced by immunization with Campylobacter jejuni lipopolysaccharide from a patient with Guillain-Barré syndrome.
Caporale CM; Capasso M; Luciani M; Prencipe V; Creati B; Gandolfi P; De Angelis MV; Di Muzio A; Caporale V; Uncini A
J Neuroimmunol; 2006 May; 174(1-2):12-20. PubMed ID: 16516981
[TBL] [Abstract][Full Text] [Related]
40. Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits.
Ang CW; Endtz HP; Jacobs BC; Laman JD; de Klerk MA; van der Meché FG; van Doorn PA
J Neuroimmunol; 2000 May; 104(2):133-8. PubMed ID: 10713352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
